Hydroxychloroquine (All indications except Antiphospholipid Syndrom)

Therapeutic terminations of pregnancy

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S13648
R52927		 Chambers (Controls unexposed, disease free), 2022 Termination of pregnancy for Medical reason at least 1st trimester prospective cohort unexposed, disease free excluded Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) Matched 1.00 [0.06;16.07] C
excluded (control group) 		1/279   1/279 2 279
ref
S13649
R52943		 Chambers (Controls unexposed, sick), 2022 Termination of pregnancy for Medical reason at least 1st trimester prospective cohort unexposed, sick Adjustment: No Indication HCQ: Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) Matched 3.01 [0.12;74.23] C 1/279   0/279 1 279
ref
S13653
R53021		 Costedoat-Chalumeau, 2003 Therapeutic abortion throughout pregnancy prospective cohort unexposed, sick Adjustment: No Indication HCQ: Any or not specified 0.10 [0.00;2.15] C 0/133   2/70 2 133
ref
Total 2 studies 0.53 [0.02;14.73] 3 412
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Chambers (Controls unexposed, sick), 2022Chambers, 2022 1 3.01[0.12; 74.23]127949%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Costedoat-Chalumeau, 2003Costedoat-Chalumeau, 2003 0.10[0.00; 2.15]213351%ROB confusion: criticalROB selection: unclearROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 56% 0.53[0.02; 14.73]34120.010.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.53[0.02; 14.73]341256%NAChambers (Controls unexposed, sick), 2022 Costedoat-Chalumeau, 2003 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.53[0.02; 14.73]341256%NAChambers (Controls unexposed, sick), 2022 Costedoat-Chalumeau, 2003 2 Tags Adjustment   - No  - No 0.53[0.02; 14.73]341256%NAChambers (Controls unexposed, sick), 2022 Costedoat-Chalumeau, 2003 2 Indication HCQ   - Any or not specified  - Any or not specified 0.10[0.00; 2.15]2133 -NACostedoat-Chalumeau, 2003 1   - Rheumatic diseases as a whole (Syst ...  - Rheumatic diseases as a whole (Systemic lupus erythematosus, Rheumatoid arthritis, Sjogren's syndrome...) 3.01[0.12; 74.23]1279 -NAChambers (Controls unexposed, sick), 2022 1 MatchedMatched 3.01[0.12; 74.23]1279 -NAChambers (Controls unexposed, sick), 2022 1 All studiesAll studies 0.53[0.02; 14.73]341256%NAChambers (Controls unexposed, sick), 2022 Costedoat-Chalumeau, 2003 20.010.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 13648

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.06; 16.07]2279 -NAChambers (Controls unexposed, disease free), 2022 1 unexposed, sick controlsunexposed, sick controls 0.53[0.02; 14.73]341256%NAChambers (Controls unexposed, sick), 2022 Costedoat-Chalumeau, 2003 20.510.01.0